ValuEngine Lowers VIVUS (VVUS) to Sell

ValuEngine cut shares of VIVUS (NASDAQ:VVUS) from a hold rating to a sell rating in a research note released on Monday morning, ValuEngine reports.

Separately, Zacks Investment Research lowered VIVUS from a buy rating to a hold rating in a research note on Wednesday, January 30th.

Shares of NASDAQ:VVUS opened at $4.03 on Monday. The company has a market cap of $42.55 million, a PE ratio of -1.16 and a beta of 2.13. VIVUS has a 12 month low of $2.15 and a 12 month high of $9.90.

VIVUS (NASDAQ:VVUS) last announced its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported ($0.75) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.17) by $0.42. The firm had revenue of $16.15 million for the quarter. As a group, research analysts expect that VIVUS will post -3.49 earnings per share for the current fiscal year.

In related news, Director Eric W. Roberts bought 8,500 shares of VIVUS stock in a transaction that occurred on Thursday, February 28th. The shares were purchased at an average price of $4.82 per share, with a total value of $40,970.00. Following the purchase, the director now owns 16,660 shares in the company, valued at $80,301.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John P. Amos bought 11,000 shares of VIVUS stock in a transaction that occurred on Friday, March 1st. The stock was bought at an average cost of $4.85 per share, for a total transaction of $53,350.00. Following the purchase, the chief executive officer now owns 1,719,500 shares in the company, valued at approximately $8,339,575. The disclosure for this purchase can be found here. 12.00% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of VVUS. JPMorgan Chase & Co. raised its holdings in VIVUS by 217.5% in the 1st quarter. JPMorgan Chase & Co. now owns 74,368 shares of the biopharmaceutical company’s stock valued at $312,000 after acquiring an additional 50,945 shares during the last quarter. Oxford Asset Management LLP raised its holdings in VIVUS by 22.4% in the 1st quarter. Oxford Asset Management LLP now owns 71,568 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 13,080 shares during the last quarter. Worth Venture Partners LLC raised its holdings in VIVUS by 67.6% in the 4th quarter. Worth Venture Partners LLC now owns 50,292 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 20,292 shares during the last quarter. Spark Investment Management LLC acquired a new position in VIVUS in the 1st quarter valued at $98,000. Finally, Virtu Financial LLC acquired a new position in VIVUS in the 4th quarter valued at $29,000. 16.66% of the stock is currently owned by hedge funds and other institutional investors.

About VIVUS

VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol.

Recommended Story: What is channel trading?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.